Sen, S., Hezel, A. F., Kasi, A., Lakhani, N. J., Spira, A. I., Veluswamy, R., Xu, C., Fujii, H., Gill, S., Lee, H., McKean, W. B. (2025). Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with
                    <i>KRAS G12D</i>
                    mutations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3178